Search

Your search keyword '"David J. Timson"' showing total 67 results

Search Constraints

Start Over You searched for: Author "David J. Timson" Remove constraint Author: "David J. Timson" Topic medicine Remove constraint Topic: medicine
67 results on '"David J. Timson"'

Search Results

1. Galactose epimerase deficiency: lessons from the GalNet registry

2. [13C]‐galactose breath test in a patient with galactokinase deficiency and spastic diparesis

3. Galactokinase deficiency

4. In SilicoAnalysis of the Effects of Point Mutations on α-Globin: Implications for α-Thalassemia

5. Therapies for galactosemia: a patent landscape

6. Repurposing drugs for the treatment of galactosemia

7. Galactosemia: Towards Pharmacological Chaperones

8. The structural and molecular biology of type IV galactosemia

9. Pilot Evaluation of Two Fasciola hepatica Biomarkers for Supporting Triclabendazole (TCBZ) Efficacy Diagnostics

10. In silico analysis of the effects of disease-associated mutations of β-hexosaminidase A in Tay‒Sachs disease

11. Novel and selective inactivators of Triosephosphate isomerase with anti-trematode activity

12. Galactosemia: opportunities for novel therapies

13. Praziquantel: An Enigmatic, Yet Effective, Drug

14. Antioxidant properties and global metabolite screening of the probiotic yeastSaccharomyces cerevisiaevar.boulardii

15. Negative Cooperativity in NAD(P)H Quinone Oxidoreductase 1 (NQO1)

16. Cancer-associated variants of human NQO1: impacts on inhibitor binding and cooperativity

17. Dynamic origins of substrate promiscuity in bacterial galactokinases

18. Escherichia coliModulator of Drug Activity B (MdaB) Has Different Enzymological Properties to Eukaryote Quinone Oxidoreductases

19. NQO1: A target for the treatment of cancer and neurological diseases, and a model to understand loss of function disease mechanisms

20. Myosin Va and spermine synthase: partners in exosome transport

21. NAD(P)H quinone oxidoreductase (NQO1): an enzyme which needs just enough mobility, in just the right places

22. UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase- 6 (pp-GalNAc-T6): Role in Cancer and Prospects as a Drug Target

23. Type IV galactosemia

24. Water-mediated network in the resistance mechanism of fosfomycin

25. Calmodulins from Schistosoma mansoni: Biochemical analysis and interaction with IQ-motifs from voltage-gated calcium channels

26. In SilicoPrediction of the Effects of Mutations in the Human Mevalonate Kinase Gene: Towards a Predictive Framework for Mevalonate Kinase Deficiency

27. Characterisation of eppin function: expression and activity in the lung

28. Natural (and Unnatural) Small Molecules as Pharmacological Chaperones and Inhibitors in Cancer

29. FAD binding overcomes defects in activity and stability displayed by cancer-associated variants of human NQO1

30. A Dynamic Core in Human NQO1 Controls the Functional and Stability Effects of Ligand Binding and Their Communication across the Enzyme Dimer

31. Triose phosphate isomerase from the blood flukeSchistosoma mansoni: Biochemical characterisation of a potential drug and vaccine target

32. Comparison of dynamics of wildtype and V94M human UDP-galactose 4-epimerase—A computational perspective on severe epimerase-deficiency galactosemia

33. Citrate synthase from the liver fluke Fasciola hepatica

34. The molecular basis of galactosemia - Past, present and future

35. Conformational dynamics is key to understanding loss-of-function of NQO1 cancer-associated polymorphisms and its correction by pharmacological ligands

36. TheGALgenetic switch: visualisation of the interacting proteins by split-EGFP bimolecular fluorescence complementation

37. Binding of serum albumin to the anthelmintic drugs albendazole, triclabendazole and their sulphoxides

38. The biochemical basis of hereditary fructose intolerance

39. The contribution of key hydrophobic residues in ecotin to enzyme-inhibitor complex stability

40. Serine Proteases in Bone Disease

41. Analysis of UDP‐galactose 4′‐epimerase mutations associated with the intermediate form of type III galactosaemia

42. Coumarin-Based Inhibitors of Human NAD(P)H:Quinone Oxidoreductase-1. Identification, Structure–Activity, Off-Target Effects and In Vitro Human Pancreatic Cancer Toxicity

43. Dicoumarol: A Drug which Hits at Least Two Very Different Targets in Vitamin K Metabolism

44. The structural and molecular biology of type III galactosemia

45. Functional analysis of disease-causing mutations in human UDP-galactose 4-epimerase

46. Molecular Structure of Human Galactokinase

47. Purple sweet potato colour – a potential therapy for galactosemia?

48. Substrate Specificity and Mechanism from the Structure of Pyrococcus furiosus Galactokinase

49. Fine tuning the myosin motor: the role of the essential light chain in striated muscle myosin

50. Identification and characterisation of human aldose 1-epimerase

Catalog

Books, media, physical & digital resources